IRCT20160813029327N10
Recruiting
Phase 3
Randomized double blind placebo controlled study of oral lithium for prevention of chemotherapy induce peripheral neuropathy in breast cancer patients under treatment by Taxans and Platinium base medicines
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Chemotherapy induce peripheral neuropathy.
- Sponsor
- Islamic Azad University
- Enrollment
- 44
- Status
- Recruiting
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Women with breast cancer between 18 to 60 years old
Exclusion Criteria
- •Dissatisfaction of patients to participate in the study
- •Pregnant or planning for pregnancy and nursing mothers
- •Patients with peripheral nerves disorders, renal disorders, thyroid disorders, cardiovascular disorders, diabetes, bipolar
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 3
Comparing the use of oral misoprostol with vaginal misoprostol to facilitate spontaneous labourCTRI/2019/01/017318Fluid Research Grant
Completed
Not Applicable
Randomized double-blind placebo-controlled study of the efficacy of food containing bovine lactoferrin for suppression of colorectal polypscolorectal polyps(adenomas)JPRN-C000000182ational cancer center105
Active, not recruiting
Not Applicable
randomized double blind placebo controlled study on the efficacy of autologous autovaccine in house dust mite allergy - FIAVSEUCTR2005-005534-12-DEThe Symbio Herborn Group GmbH24
Not yet recruiting
Phase 3
The Shepherd Foundation Study into Alzheimer's DiseaseACTRN12606000324516Melbourne Health60
Active, not recruiting
Phase 1
Randomized double blind placebo-controlled study to demonstrate that antibiotics are not needed in moderate acute exacerbations of COPD – The ABACOPD StudyMedDRA version: 19.0 Level: LLT Classification code 10010953 Term: COPD exacerbation System Organ Class: 100000004855Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2012-003234-16-DEHannover Medical School represented by Hannover Clinical Trial Center GmbH980